In the survival analysis of all uterine serous carcinoma patients, those with CCNE1 amplification had significantly shorter median overall survival (97.3 months vs 44.3; HR (95%CI): 7.1 (10.03, 59.4) p< 0.05) (Figure 4). Here, CCNE1 is linked to endometrial serous adenocarcinoma.